Frequency of Dyslipidemia among patients with Rheumatoid Arthritis in Lady Reading Hospital Peshawar
Dyslipidemia in patients with Rheumatoid Arthritis
DOI:
https://doi.org/10.52442/jrmi.v11i1.643Keywords:
Cholesterol, Dyslipidemia, High Density Lipoproteins, Low Density Lipoproteins, Rheumatoid Arthritis, TriglycerideAbstract
Introduction: Autoimmune diseases characterized by chronic inflammation, such as Rheumatoid Arthritis (RA), frequently exhibit altered lipid profiles, suggesting a complex interplay between immune response and lipid metabolism. It is well-established that RA patients often present with abnormal lipid levels; however, the precise frequency of dyslipidemia in the local population of Peshawar has not been thoroughly investigated.
Objective: This study aimed to determine the frequency of dyslipidemia among patients with rheumatoid arthritis in a tertiary care set-up in Peshawar.
Materials & Methods: This cross-sectional study was conducted over six months from July 2022 to January 2023 in the Department of Medicine, Lady Reading Hospital, Peshawar. A total of 185 patients with RA were included in the study using consecutive sampling. Patients were tested for dyslipidemia based on their lipid profile, including total cholesterol, triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL). Dyslipidemia was defined according to standard clinical guidelines, where elevated levels of total cholesterol, TG, LDL, or decreased levels of HDL, indicated dyslipidemia.
Results: The mean age of the sample was 46.4 ± 8.2 years, with 61.6% males and 38.4% females. The mean serum cholesterol was 164.5 ± 31.5 mg/dL, mean serum TG was 130.2 ± 32.6 mg/dL, mean LDL was 85.2 ± 28.1 mg/dL, and mean HDL was 53.3 ± 12.1 mg/dL. Dyslipidemia was recorded in 24.9% of the patients.
Conclusion: Dyslipidemia is common among RA patients in our local population. These findings suggest the need for regular lipid profile screening and early intervention in RA patients to mitigate the risk of cardiovascular complications associated with dyslipidemia.
References
Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res Ther. 2002;4(S3):1-8. doi: 10.1186/ar578
Finckh A, Gilbert B, Hodkinson B, Bae S-C, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591-602. doi: 10.1038/s41584-022-00827-y.
Nilsson J, Andersson ML, Hafström I, Svensson B, Forslind K, Ajeganova S, et al. Influence of age and sex on disease course and treatment in rheumatoid arthritis. Open Access Rheumatol. 2021:123-38. doi: 10.2147/OARRR.S306378.
Kerekes G, Nurmohamed MT, González-Gay MA, Seres I, Paragh G, Kardos Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10(11):691-6. doi: 10.1038/nrrheum.2014.121
Steiner G, Urowitz MB, editors. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Seminars Arthritis Rheum. 2009;38(5):372-81. doi: 10.1016/j.semarthrit.2008.01.015.
Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol. 2013;9(9):513-23. doi: 10.1038/nrrheum.2013.91.
Arts AEE, Popa CD, Smith JP, Arntz OJ, van de Loo FA, Donders R, et al. Serum samples that have been stored long-term (> 10 years) can be used as a suitable data source for developing cardiovascular risk prediction models in large observational rheumatoid arthritis cohorts. Biomed Res Int. 2014;2014:930925. doi: 10.1155/2014/930925.
Pappas DA, John A, Kremer J, Reed G, Greenberg J, Shewade A, et al. Dyslipidemia, Inflammation and Cardiovascular Risk in Patients with Rheumatoid Arthritis. Pharmacoepidemiol. Drug Saf. 2013;22:5.
Hameed SB, Al-Barzinjy NJ. Prevalence of dyslipidemia and its association with disease activity in patients with rheumatoid arthritis attending Rizgary Teaching Hospital in Erbil City. Zanco J Med Sci. 2017;21:1781-8.
Akiyama M, Mawatari T, Nakashima Y, Miyahara H, Yamada H, Okazaki K, et al. Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment. Clin Rheumatol. 2015;34(11):1867-75. doi.org/10.1007/s10067-015-3049-0
Erum U, Ahsan T, Khowaja D. Lipid abnormalities in patients with Rheumatoid Arthritis. Pak J Med Sci. 2017;33(1):227-30. doi: 10.12669/pjms.331.11699
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. JACC. 2019;73(24):e285-e350.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. PMID: 12485966.2002.
Alam SM, Kidwai AA, Jafri SR, Qureshi BM, Sami A, Qureshi HH, et al. Epidemiology of rheumatoid arthritis in a tertiary care unit, Karachi, Pakistan. J Pak Med Assoc. 2011;61(2):123-6. PMID: 21375157.
Goud T. Prevalence of Rheumatoid Arthritis and DMARDs Usage in Indian Population: A Cross-Sectional Study. Asian Journal of Pharmaceutics (AJP). 2021;15(3).
Zafar ZA, Asghar A, Rehman A, Bashir B, Anwar T. Dyslipidemia in cohorts of rheumatoid arthritis presented at Independent University Hospital Faisalabad. Professional Med J. 2024;31(08):1248-54.
Hussain R, Fahad M, Nawaz A, Zahid A. Are different Metabolic Syndromes, associated with Rheumatoid Arthritis? Isra Med J. 2021;13(2).
Xie B, He J, Liu Y, Liu T, Liu C. A meta-analysis of HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis. Lipids Health Dis. 2021; 20:18. doi: 10.1186/s12944-021-01444-6.
Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, et al. Systemic complications of rheumatoid arthritis: focus on pathogenesis and treatment. Front Immunol. 2022;13:1051082. doi: 10.3389/fimmu.2022.1051082.
Johri N, Varshney S, Gandha S, Maurya A, Mittal P, Jangra S, et al. Association of cardiovascular risks in rheumatoid arthritis patients: Management, treatment and future perspectives. Health Sci Rev. 2023; 8(10):100108. doi:10.1016/j.hsr.2023.100108.
Nisar A, Rasheed U, Aziz W, Farooqi AZ. Prevalence of dyslipidemias in autoimmune rheumatic diseases. JCPSP. 2012;22(4):235-9. PMID: 22482380.
Sarfraz M, Sajid S, Ashraf MA. Prevalence and pattern of dyslipidemia in hyperglycemic patients and its associated factors among Pakistani population. Saudi J Biol Sci. 2016;23(6):761-6. doi: 10.1016/j.sjbs.2016.03.001.
Venetsanopoulou AI, Pelechas E, Voulgari PV, Drosos AA. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020;40(8):1181-91. doi: 10.1007/s00296-020-04616-2.
Konstantonis G, Singh KV, Sfikakis PP, Jamthikar AD, Kitas GD, Gupta SK, et al. Cardiovascular disease detection using machine learning and carotid/femoral arterial imaging frameworks in rheumatoid arthritis patients. Rheumatol Int. 2022;42(2):215-39. doi: 10.1007/s00296-021-05062-4.
Letarouilly JG, Flipo RM, Cortet B, Tournadre A, Paccou J. Body composition in patients with rheumatoid arthritis: a narrative literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720x211015006. doi: 10.1177/1759720X211015006.
Rezuș E, Macovei LA, Burlui AM, Cardoneanu A, Rezuș C. Ischemic heart disease and rheumatoid arthritis—two conditions, the same background. Life. 2021;11(10):1042. doi: 10.3390/life11101042.
Mullick OS, Bhattacharya R, Bhattacharyya K, Sarkar RN, Das A, Chakraborty D, et al. Lipid profile and its relationship with endothelial dysfunction and disease activity in patients of early Rheumatoid Arthritis. Indian J Rheumatol. 2014;9(1):9-13. doi: 10.1016/j.injr.2014.01.003
Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev. 2021;20(2):102735. doi: 10.1016/j.autrev.2020.102735.
Maeda K, Yoshida K, Nishizawa T, Otani K, Yamashita Y, Okabe H, et al. Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments. Int J Mol Sci. 2022;23(5):2871. doi: 10.3390/ijms23052871.
Qiu J, Wu B, Goodman SB, Berry GJ, Goronzy JJ, Weyand CM. Metabolic control of autoimmunity and tissue inflammation in rheumatoid arthritis. Front Immunol. 2021;12:652771. doi: 10.3389/fimmu.2021.652771
